A study conducted by Rigshospitalet, Denmark, aimed to evaluate the development of hemolysis and variation in isokinetic muscle strength in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy (MMN). The study involved two groups of patients: those shifted from 3- or 6-weekly treatment with intravenous immunoglobulin (IVIG) to weekly treatment with subcutaneous immunoglobulin (SCIG), and those shifted from SCIG treatment with Subcuvia or Hizentra to Gammanorm. The study, which was completed in 2015, had 36 participants and was sponsored by Rigshospitalet, Denmark, in collaboration with Aarhus University Hospital and Octapharma Pharmazeutika Produktionsges.m.b.H.
---
Source: ClinicalTrials.gov
每日新闻2026年8月23日•3 分钟阅读
CIDP and MMN Immunoglobulin Study
A completed study evaluates immunoglobulin dosage in CIDP and MMN patients. The study compares IVIG and SCIG treatments.
由 Pharmacountry 团队整理 · 来源： ClinicalTrials.gov
主题：
评分
(0)
(0)
(0)
(0)
(0)
留下您的评分